Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II camrelizumab + apatinib in recurrent or metastatic adrenocortical carcinoma
ChiCTR1900028111Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in adrenal cancer (ACC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective response rate. Started Jan 2020; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on ChiCTR1900028111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028111.